Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, posted on X:
“Flatiron analysis of 34,510 patients with NSCLC on biomarker testing JCO Oncology Practice by Sandip Patel.
Steady rise in biomarker testing: in 2023, 89% tested for EGFR and 88% for ALK. Not all receive targeted therapy though: only 84% of ALK+ receive an ALK TKI.”
Title: Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States
Authors: Michael J. Dennis, Devin Abrahami, Maria Cecilia Vieira, Darrin Benjumea, Marley Boyd, Anran Shao, John Kelton, Sandip Pravin Patel
Read The Full Article at JCO Oncology.
More posts featuring Stephen Liu.